GlaxoSmithKline | GSK - Ordinary Share Capital


GlaxoSmithKline reported GBP4.05B in Ordinary Share Capital for its fiscal quarter ending in March of 2026.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Alcon AG USD 487.4M 0 Mar/2026
Almirall EUR 214.79M 0 Dec/2025
Amgen USD 540M 1000K Mar/2026
AstraZeneca USD 1.55B 73K Mar/2026
Bayer EUR 982.42M 0 Dec/2025
Biogen USD 146.7M 200K Sep/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Eli Lilly USD 943.5M 3.33M Mar/2026
Fresenius EUR 563.24M 0 Dec/2025
Fresenius Medical Care EUR 270.09M 9.2M Mar/2026
Genmab DKK 61.62M 52K Dec/2025
Gilead Sciences USD 1.24B 1000K Mar/2026
GlaxoSmithKline GBP 4.05B 20.6M Mar/2026
Glaxosmithkline GBP 4.08B 49.43M Dec/2025
GRIFOLS EUR 680.58M 0 Mar/2026
Hikma Pharmaceutical USD 221.89M 181.89M Dec/2025
Lakefront Biotherapeutics EUR 65.9M 0 Mar/2026
Lonza CHF 68.64M 0 Dec/2025
Merck EUR 434.78M 0 Mar/2026
Merck USD 2.47B 12.72M Dec/2025
Novartis USD 1.91B 60K Mar/2026
Novo Nordisk DKK 4.44B 0 Dec/2025
Orion EUR 140.87M 173K Mar/2026
Pfizer USD 5.7B 13M Mar/2026
Philips EUR 952.02M 729K Mar/2026
Recordati EUR 203.43M 928K Mar/2026
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Roche Holding CHF 795.62M 699.54K Dec/2025
Sanofi EUR 1.21B 8.25M Mar/2026
Smith & Nephew USD 875.96M 1.61M Dec/2025
UCB EUR 190.36M 365.15K Dec/2025